MAIA Biotechnology, a leading clinical-stage biotech firm specializing in telomere-targeting immunotherapies for cancer, unveiled encouraging preliminary efficacy data today from its ongoing Phase 2 clinical trial, THIO-101. This trial assesses the potential of THIO in combination with Regeneron’s anti-PD-1 cemiplimab (Libtayo) in patients grappling with advanced Non-Small Cell Lung Cancer (NSCLC).
The key findings of the trial are highly promising. A remarkable 100% Preliminary Disease Control Rate (DCR) was observed in second-line treatment, with an equally impressive 88% in third-line treatment. These results are particularly noteworthy as they pertain to patients who had already progressed through previous lines of treatment, presenting a formidable challenge to therapeutic interventions.
Notably, DCRs across all dose levels met the pre-established statistical criteria earlier than anticipated, signaling a significant milestone for the progression of the trial. “In NSCLC patients who received at least one line of therapy, DCRs have shown to be excellent predictors of overall survival,” affirmed Vlad Vitoc, M.D., MAIA’s Chief Executive Officer. He further emphasized the groundbreaking nature of the results, highlighting that the observed 100% DCR in second-line treatment eclipses the conventional rates for Standard of Care (SoC), which typically range from 53-64%.
Additionally, the preliminary data showcased an unprecedentedly high DCR of 88% in third-line treatment when THIO was administered followed by cemiplimab. Notably, these patients had previously experienced treatment failure with a checkpoint inhibitor. While there is currently no established Standard of Care for third-line treatment, earlier studies have reported an approximate 30% DCR. These outstanding results reinforce the confidence of MAIA Biotechnology in advancing the clinical trial to benefit advanced-stage NSCLC patients.
This groundbreaking data was unveiled at the European Society for Medical Oncology (ESMO) Congress 2023, held in Madrid, Spain, on October 23, 2023.
In parallel developments, Market Screener has reported that certain Common Stock of MAIA Biotechnology, Inc. will become unrestricted after the conclusion of a Lock-Up Agreement on October 24, 2023. These Common Stock units were subject to a lock-up period spanning 183 days, commencing from April 24, 2023, until October 24, 2023.
In the financial domain, MAIA Biotechnology experienced a rally in its stock price, culminating in a closing figure of $2.03 USD on the preceding day. However, the stock has experienced a decline in today’s trading session, currently holding at $1.50 USD.
At the time of this publication, Maia Biotechnology Inc stock (MAIA) has witnessed a decline.
MAIA
Maia Biotechnology Inc
Current Price: $1.50
Change : -0.53
Change (%): (-26.11%)
Volume: 448.4K
Source: Tomorrow Events Market Data
